Skip to main content
. 2022 Oct 1;13(5):1523–1531. doi: 10.14336/AD.2022.0205

Table 6.

Adverse effects following bamlanivimab infusion.

Participant Consent and Dosage Adverse Effects, n (%) Nausea Vomiting Diarrhea Dizziness Hospitalizations Death Age, Mean
Consented and received treatment 44 5 (11.36%) 4 1 1 1 1 0 76.6
Full dose 39 4 (10.26%) 3 1 1 1 0 0 71
Incompletedose 5 1 (20.00%) 1 0 0 0 1 0 99